PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 22, 2025Molecular Pharmaceutics2 citations

Triple-Responsive Cross-Linked Micelles for Synergistic Chemo-Photothermal Cancer Therapy

View Full Paper
YOYu‐Che OuYWYudong WangKCKanglin Chen

Key Points

  • The DCM micelles significantly inhibited tumor growth compared to other treatment groups, demonstrating effective synergy.
  • In B16 tumor-bearing mice, the DCM + NIR group achieved over 70% survival after 40 days, highlighting its effectiveness.
  • The unique design of DCMs allows for rapid drug release and enhanced stability under physiological conditions, improving treatment outcomes.
  • With minimal systemic toxicity, this innovative therapy presents a promising advancement for targeted cancer treatment.

Abstract

We have developed a novel triple-responsive (pH/reduction/near-infrared (NIR) light) cross-linked polymer micelle PEG-P(LL/LL-LA)-PCL-IR820 for enhanced synergistic cancer therapy. This micelle was synthesized using a triblock amphiphilic polymer based on polylysine, functionalized with maleic anhydride (LA) as a cross-linking site and polycaprolactone (PCL) for encapsulating the anticancer drug doxorubicin (DOX). The photosensitizer IR820 was grafted onto PCL to enable photothermal and photodynamic effects under NIR irradiation. The DOX-loaded cross-linked micelles (DCMs) demonstrated exceptional stability under physiological conditions, effectively preventing premature drug release. Rapid DOX release was triggered by the intracellular high glutathione (GSH) level and acidic pH in tumor cells. Under NIR irradiation, DCM micelles exhibited significant photothermal and photodynamic effects, which markedly enhanced the cytotoxicity against B16 tumor cells. In B16 tumor-bearing mice, the DCM-treated group achieved superior tumor growth inhibition and prolonged survival under NIR irradiation compared to un-cross-linked micelles (DUCM) or free DOX, with minimal systemic toxicity. The tumor volume in the DCM + NIR group was significantly inhibited compared with other groups, reaching only about 300 mm3 within 15 days, while for the PBS-treated group, it reached approximately 1400 mm3. The survival rate of the DCM + NIR group was also significantly higher, with an over 70% survival rate within a 40-day observation period. This work presents a robust nanoplatform that combines stability, microenvironment responsiveness, and multimodal therapy, offering a promising strategy for targeted cancer treatment.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ou et al. (2025) studied this question.

synapsesocial.com/papers/68d46fdc31b076d99fa6a43dhttps://doi.org/10.1021/acs.molpharmaceut.5c01130
Ask AI
Helpful
Bookmark
Share
View Full Paper